CD86 and myocardial infarction: Moreover, DMOG treatment for 7 days after MI significantly increased the ratio of CXCR4-EGFP+ CD11b+/CD206+ cells to CD11b+/CD86+ cells by 2.6-fold from 0.7 to 1.82 compared with infarcted control animals, suggesting an improved fine-tuning of reparative M2-like CD206+ compared to inflammatory CD86+ cells in the ischemic heart (Fig. 4e).